News

Biogen Announces Webcast of Annual Meeting of Stockholders

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in South Korea

Biogen to Participate in the Jefferies Global Healthcare Conference

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Statement: Biogen Shares Update on Angelman Syndrome Program

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis